DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for macrocytic anemia — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMacrocytic anemia maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for macrocytic anemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
thyroid hormone receptor alpha (THRA) — THRA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1-methylethyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3ILZ · 1.85 Å · ligand {4-[4-hydroxy-3-(1-methylethyl)benzyl]-3,5-dimethylphenoxy}acetic acid (B72). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2019 · 2 citations
[Etiologyical Analysis of 133 Patients with Elderly Macrocytic Anemia and Diagnostic Significance of Laboratory Tests].
AbstractOBJECTIVE: To study the etiology of macrocytic anemia in elderly patients and to evaluate the diagnostic significance of laborotory tests. METHODS: 133 elderly macrocytic anemia patients, whose age>60 years old, hemoglobin<100 g/L, mean red cell volume(MCV)>100 fL, and bone marrow cell test was performed, and these patients were grouped according to diseases, and the bilirubin, lactate dehydrogenase, folic acid, vit B12 and serum ferritin were tested, then the results of tests were compared and analyzed. RESULTS: The majority of the cases were diagnosed as megaloblastic anemia (MA), myelodysplasia syndrome (MDS), acute leukemia/multiple myeloma (AL/MM) and hemolytic anemia (HA). Usually HA was a simple anemia, while others were accompanied by decrease of other 1 or 2 series. HA patients were often with significant high level of well volume (MCV), red cell distribution width(RDW), reticulocytes (RC) and indirect bilirubin (IBIL) (P<0.01). However, MA patients were often with high level of LDH. Serum ferritin (SF) level was significantly higher in both MDS and AL/MM groups (P<0.01). CONCLUSION: Common causes of macrocytic anemia in elderly patients are MA, MDS, AL/MM and HA. The combination detection of MCV, RDW, RC, LDH, IBIL and SF contributes to enhancing the accuracy of diagnosis.
Zenodo (CERN European Organization for Nuclear Research) · 2022 · 0 citations · open access
Macrocytic anemia: Myelogram results in military hospital Avicenna in Marrakech
AbstractAnemia is one of the most common health problems in the primary care setting. Macrocytosis in adults is defined as a red blood cell mean corpuscular volum >95 fL. Macrocytic anemias are generally classified into megaloblastic or non-megaloblastic anemia. Retrospective descriptive study included 340 samples of myelogram received in the Hematology Labortory belonging to patients admitted to the Military hospital of Avicenna in Marrakech, over a period of 48 months (from January 2016 to January 2020), aimed to assess the etiological profile of macrocytic anemia in patients whose bone marrow smears were received in our laboratory. Out of 340 myelogram samples, 120 cases of macrocytic anemia were received. The male gender was predominant with a sex-ratio (M/F) at 3. The average age was 55 years old with extremes ranging from 29 to 91 years? The discovery of macrocytic anemia was fortuitous in 30% of cases. 47% of our population presented anemic syndrom, 14% hemorrhagic syndrome, 9% infectious syndrome. The hemoglobin varyied between 4,7 g/dL and 11,9 g/dL with an average of 7.2 g/dL. The mean corpuscular volume was 107 fL. The bone marrow smear confirmed megaloblastic anemia in 54,3% of cases of macrocytic anemia. The diversity and complexity of factors leading to macrocytic anemia preclude a single or uniform method of investigation. The investigative pattern must be tailored to the individual patient, giving importance to the clinical presentation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
